CollPlant Biotechnologies (CLGN) Q1 2025 earnings summary

Executive summary

• Achieved a $2 million milestone payment from AbbVie in Q1 2025 for dermal filler development progress.

• Advanced regenerative breast implant program with promising preclinical results and refined surgical protocols.

• Initiated cost-cutting and workforce reduction plan, reducing workforce by 20% to extend cash runway into Q2 2026.

• Expanded international distribution for VergenixSTR and strengthened IP portfolio with new patents in the US and Japan.

Financial highlights

• Q1 2025 GAAP revenue was $2.1 million, up from $98,000 in Q1 2024, mainly due to the AbbVie milestone.

• GAAP gross profit was $1.9 million versus a gross loss of $447,000 in Q1 2024.

• GAAP net loss was $1.5 million ($0.13/share) compared to $4.2 million ($0.37/share) in Q1 2024.

• Non-GAAP net loss was $1.1 million ($0.10/share) versus $4.0 million ($0.35/share) in Q1 2024.

• Cash and cash equivalents at March 31, 2025, were $10.7 million.

Outlook and guidance

• Focused on advancing core programs and pursuing non-dilutive financing to support long-term growth.

• Plans to optimize regenerative breast implants for long-term tissue remodeling and durability.

• Preparing for clinical studies of the photocurable dermal filler, with production scale-up underway.